Share:
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has joined the FLAMIN-GO Project consortium of academic and industry leaders in rheumatology, autoimmune disease research, and drug discovery and development to create an organ-on-a-chip solution toward personalized care and improved outcomes for rheumatoid arthritis (RA) patients.
Organ-on-a-chip refers to a microfluidic culture device that simulates the microarchitecture and functions of living human organs, potentially offering an alternative to traditional animal testing.
RA, an autoimmune inflammatory disorder characterized by synovial joint inflammation, affects ~0.5 to 1 percent of the global population. RA is a significant public health problem as it can lead to permanent disability. To gain insights into this disease, FLAMIN-GO Project